Disclosures

JDC is a current member of the Scientific Advisory Board of OpenEye Scientific Software and Founder and CEO of Achira, and has equity interests in Achira and PICO Therapeutics. As a scientific advisor or invited speaker, he has received consulting or speaking fees from Abbvie, Astex, Boehringer-Ingelheim, Blueprint Medicines, Celgene, Foresite Capital, Foresite Labs, Interline Therapeutics, MPM Capital, OpenEye Scientific, Schrödinger, and Ventus Therapeutics.

The Chodera laboratory receives or has received funding from multiple sources, including the National Institutes of Health, the National Science Foundation, the Parker Institute for Cancer Immunotherapy, Relay Therapeutics, Entasis Therapeutics, Silicon Therapeutics, EMD Serono (Merck KGaA), AstraZeneca, Vir Biotechnology, Bayer, XtalPi, Interline Therapeutics, the Molecular Sciences Software Institute, the Starr Cancer Consortium, the Open Force Field Consortium, Cycle for Survival, a Louis V. Gerstner Young Investigator Award, and the Sloan Kettering Institute.

A complete funding history for the Chodera lab can be found at http://choderalab.org/funding.